Free tool
FAERS Monitor: Ultomiris
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761108 or its brand name (Ultomiris, Ravulizumab-Cwvz). Reports on generic versions are filed under their own applications.
Reports
14,195
Serious
8,138
57% of reports
Hospitalization
2,863
Death reported
1,058
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,819
- asthenia925
- drug ineffective775
- headache772
- death677
- off label use581
- dyspnoea548
- muscular weakness532
- myasthenia gravis511
- malaise483
- pain452
- haemoglobin decreased423
- back pain395
- feeling abnormal379
- diarrhoea368
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2018 | 2 |
| 2019 | 599 |
| 2020 | 434 |
| 2021 | 433 |
| 2022 | 512 |
| 2023 | 2,079 |
| 2024 | 4,319 |
| 2025 | 3,090 |
| 2026 | 2,726 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,964 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myasthenia gravisSignal | 511 | 100.0 | 91.6 | 46,843 |
| muscular weaknessSignal | 532 | 7.0 | 6.4 | 2,713 |
| haemoglobin decreasedSignal | 423 | 6.1 | 5.6 | 1,810 |
| astheniaSignal | 925 | 3.7 | 3.4 | 1,806 |
| fatigueSignal | 1,819 | 3.5 | 3.3 | 3,307 |
| back painSignal | 395 | 2.5 | 2.3 | 365 |
| feeling abnormalSignal | 379 | 2.3 | 2.1 | 294 |
| headache | 772 | 1.8 | 1.7 | 296 |
| malaise | 483 | 1.6 | 1.5 | 120 |
| dyspnoea | 548 | 1.4 | 1.3 | 74 |
| death | 677 | 1.2 | 1.1 | 16 |
| pain | 452 | 1.1 | 1.0 | 3 |
| off label use | 581 | 1.0 | 0.9 | 0 |
| drug ineffective | 775 | 0.9 | 0.8 | 16 |
| diarrhoea | 368 | 0.8 | 0.8 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.